{"id":5469,"date":"2020-07-31T08:43:00","date_gmt":"2020-07-31T08:43:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&p=5469"},"modified":"2024-05-02T10:27:17","modified_gmt":"2024-05-02T08:27:17","slug":"targeting-of-cd163-macrophages-in-inflammatory-and-malignant-diseases","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/es\/professional\/scientific-corner\/targeting-of-cd163-macrophages-in-inflammatory-and-malignant-diseases\/","title":{"rendered":"Targeting of CD163+ Macrophages in Inflammatory and Malignant Diseases"},"content":{"rendered":"
\n

Maria K. Skytthe<\/a>,1<\/sup> Jonas Heilskov Graversen<\/a>,1,*<\/sup> and S\u00f8ren K. Moestrup<\/a>, Int J Mol Sci.<\/a> 2020 Aug; 21(15): 5497.<\/p>\n<\/div>\n\n

\n

In conclusion, the specific targeting of CD163+<\/sup> macrophages has been demonstrated to be a promising drug delivery strategy for handling inflammatory and malignant disease, contributing to the current pharmaceutical therapies.<\/p>\n<\/div>\n\n

\n

(nih.gov)https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7432735\/<\/a><\/p>\n<\/div>\n\n

\n

https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7432735\/pdf\/ijms-21-05497.pdf<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Maria K. Skytthe,1 Jonas Heilskov Graversen,1,* and S\u00f8ren K. Moestrup, Int J Mol Sci. 2020 Aug; 21(15): 5497. In conclusion, the specific targeting of CD163+ macrophages has been demonstrated to be a promising drug delivery strategy for handling inflammatory and malignant disease, contributing to the current pharmaceutical therapies. (nih.gov)https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7432735\/ https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7432735\/pdf\/ijms-21-05497.pdf<\/p>\n","protected":false},"template":"","scientific_tags":[324,323,102,312],"class_list":["post-5469","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-cancer","scientific_tags-cd163","scientific_tags-glucocorticoid","scientific_tags-immunology"],"acf":{"sc_authors":"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7432735\/<\/a>\r\n\r\nhttps:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7432735\/pdf\/ijms-21-05497.pdf<\/a>"},"yoast_head":"\nTargeting of CD163+ Macrophages in Inflammatory and Malignant Diseases - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/targeting-of-cd163-macrophages-in-inflammatory-and-malignant-diseases\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Targeting of CD163+ Macrophages in Inflammatory and Malignant Diseases - Adacyte\" \/>\n<meta property=\"og:description\" content=\"Maria K. Skytthe,1 Jonas Heilskov Graversen,1,* and S\u00f8ren K. Moestrup, Int J Mol Sci. 2020 Aug; 21(15): 5497. In conclusion, the specific targeting of CD163+ macrophages has been demonstrated to be a promising drug delivery strategy for handling inflammatory and malignant disease, contributing to the current pharmaceutical therapies. (nih.gov)https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7432735\/ https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7432735\/pdf\/ijms-21-05497.pdf\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/targeting-of-cd163-macrophages-in-inflammatory-and-malignant-diseases\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2024-05-02T08:27:17+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/targeting-of-cd163-macrophages-in-inflammatory-and-malignant-diseases\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/targeting-of-cd163-macrophages-in-inflammatory-and-malignant-diseases\/\",\"name\":\"Targeting of CD163+ Macrophages in Inflammatory and Malignant Diseases - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2020-07-31T08:43:00+00:00\",\"dateModified\":\"2024-05-02T08:27:17+00:00\",\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/targeting-of-cd163-macrophages-in-inflammatory-and-malignant-diseases\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Targeting of CD163+ Macrophages in Inflammatory and Malignant Diseases - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/targeting-of-cd163-macrophages-in-inflammatory-and-malignant-diseases\/","og_locale":"es_ES","og_type":"article","og_title":"Targeting of CD163+ Macrophages in Inflammatory and Malignant Diseases - Adacyte","og_description":"Maria K. Skytthe,1 Jonas Heilskov Graversen,1,* and S\u00f8ren K. Moestrup, Int J Mol Sci. 2020 Aug; 21(15): 5497. In conclusion, the specific targeting of CD163+ macrophages has been demonstrated to be a promising drug delivery strategy for handling inflammatory and malignant disease, contributing to the current pharmaceutical therapies. (nih.gov)https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7432735\/ https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7432735\/pdf\/ijms-21-05497.pdf","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/targeting-of-cd163-macrophages-in-inflammatory-and-malignant-diseases\/","og_site_name":"Adacyte","article_modified_time":"2024-05-02T08:27:17+00:00","twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/targeting-of-cd163-macrophages-in-inflammatory-and-malignant-diseases\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/targeting-of-cd163-macrophages-in-inflammatory-and-malignant-diseases\/","name":"Targeting of CD163+ Macrophages in Inflammatory and Malignant Diseases - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2020-07-31T08:43:00+00:00","dateModified":"2024-05-02T08:27:17+00:00","inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/targeting-of-cd163-macrophages-in-inflammatory-and-malignant-diseases\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner\/5469","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/media?parent=5469"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific_tags?post=5469"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}